GLP1R and sarcopenia: On the other hand, some of them—metformin, GLP-1 RAs, and SGLT2i—have a potential detrimental effect on the risk of sarcopenia since they help to decrease body weight by reducing energy intake or increasing glucose excretion by glycosuria, negatively impacting on muscle mass.